Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.59−0.19 (-10.67%)
Close on Nov 18, 2026Market cap $52.03MP/E –Yield –
Insight Molecular Diagnostics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Insight Molecular Diagnostics's operating income for the twelve months ending Jun 30, 2026 was -$50.30M. For fiscal 2025 it was -$51.12M. The highest annual figure on record is -$4.97M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.12M | – |
| FY2024 | Dec 31, 2024 | -$61.04M | – |
| FY2023 | Dec 31, 2023 | -$25.14M | – |
| FY2022 | Dec 31, 2022 | -$18.00M | – |
| FY2021 | Dec 31, 2021 | -$53.73M | – |
| FY2020 | Dec 31, 2020 | -$29.71M | – |
| FY2019 | Dec 31, 2019 | -$22.24M | – |
| FY2018 | Dec 31, 2018 | -$15.20M | – |
| FY2017 | Dec 31, 2017 | -$18.85M | – |
| FY2016 | Dec 31, 2016 | -$11.14M | – |
| FY2015 | Dec 31, 2015 | -$8.72M | – |
| FY2014 | Dec 31, 2014 | -$4.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.52M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.27M | -258.4% |
| Q4 FY2023 | Dec 31, 2023 | -$16.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.29M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.43M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.26M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.23M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.89M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.59M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.09M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.58M | – |
See a number that looks wrong?